TFC Financial Management’s Soleno Therapeutics SLNO Stock Holding History

TFC Financial Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$47	–	1059
2025 Q4	$47	Hold	1	–	–	﹤0.01%	934
2025 Q3	$68	Hold	1	–	–	﹤0.01%	946
2025 Q2	$84	Hold	1	–	–	﹤0.01%	911
2025 Q1	$72	Hold	1	–	–	﹤0.01%	872
2024 Q4	$45	Hold	1	–	–	﹤0.01%	912
2024 Q3	$51	Buy	+1	New	+$48	﹤0.01%	925

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

TFC Financial Management's SLNO Position: Q1 2026 in Review

TFC Financial Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 1 share — an estimated $47 sold.

TFC Financial Management first reported a position in SLNO in Q3 2024 and held it in 6 quarters. The position peaked at $84 in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

TFC Financial Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
TFC Financial Management sold 1 Soleno Therapeutics share in Q1 2026, an estimated $47.
TFC Financial Management first reported a position in Soleno Therapeutics in Q3 2024 and held it in 6 quarters.
TFC Financial Management's Soleno Therapeutics position peaked at $84 in Q2 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on TFC Financial Management's 13F filing for Q1 2026, filed 23 Apr 2026.